[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 018″]
The FDA turned away Alimera Sciences’ bid to market Iluvien as a treatment for diabetic macular edema three times before finally giving the green light. President & CEO Dan Myers shares what kept his confidence up during this lengthy review and how Alimera Sciences is positioning Iluvien in the DME market.
Dan Myers is the Co-Founder, President, and CEO of Alimera Sciences, Inc. Under Dan’s leadership Alimera has commercially launched ILUVIEN®, Alimera’s lead product, in the US, UK, Germany and Portugal with Marketing Authorizations in an additional 14 countries throughout the EU.